CJC-1295 with DAC and Ipamorelin are two peptides that work on completely separate receptor systems within the same organ — the pituitary gland. Their combination produces 40% greater growth hormone elevation than either compound alone, addressing the core hormonal decline that drives every major aging marker in companion animals.
Shop Now View Dosing GuideCJC-1295 with DAC is a synthetic analog of growth hormone releasing hormone (GHRH). The DAC (Drug Affinity Complex) modification adds an albumin-binding domain that makes the peptide invisible to the enzyme (DPP4) that would otherwise destroy it within minutes. Once bound to albumin — the most abundant protein in the bloodstream — CJC-1295 circulates for 7–14 days per injection, providing consistent pituitary stimulation.
Ipamorelin works on the ghrelin receptor (GHSR1A) — a completely different pathway from CJC-1295. This dual-pathway stimulation is critical: hitting only one receptor causes rapid tachyphylaxis (adaptation). Activating both pathways simultaneously slows this adaptation and produces a compounded signaling effect. The result is 40% greater GH output than either compound alone.
The downstream GH and IGF-1 elevation drives: increased lean mass through satellite cell activation, improved insulin sensitivity through GLUT4 translocation, enhanced mitochondrial biogenesis through PGC-1alpha upregulation, and improved immune function through NK cell and T-cell activation.
| Weight | Species | Dose | Frequency | Administration |
|---|---|---|---|---|
| Under 20 lbs | Dog / Cat | CJC: 1 mcg/kg / Ipa: 100 mcg | Weekly (CJC) / 3x week (Ipa) | Subcutaneous |
| 20–50 lbs | Dog | CJC: 1–2 mcg/kg / Ipa: 200 mcg | Weekly (CJC) / 3x week (Ipa) | Subcutaneous |
| 50–100 lbs | Dog | CJC: 2 mcg/kg / Ipa: 300 mcg | Weekly (CJC) / 3x week (Ipa) | Subcutaneous |
| Over 100 lbs | Dog | CJC: 2 mcg/kg / Ipa: 300 mcg | Weekly (CJC) / 3x week (Ipa) | Subcutaneous |
| Under 10 lbs | Cat | CJC: 1 mcg/kg / Ipa: 75 mcg | Weekly (CJC) / 3x week (Ipa) | Subcutaneous |